annual

GREATER DES MOINES PARTNERSHIP ANNUAL DINNER SPEAKER ANNOUNCED

GREATER DES MOINES, Iowa, Nov. 20, 2024 /PRNewswire/ -- The Greater Des Moines Partnership has announced that its 2025 Annual…

13 hours ago

GREATER DES MOINES PARTNERSHIP ANNUAL DINNER SPEAKER ANNOUNCED

GREATER DES MOINES, Iowa, Nov. 20, 2024 /PRNewswire/ -- The Greater Des Moines Partnership has announced that its 2025 Annual…

15 hours ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq:…

5 days ago

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 (GLOBE…

1 week ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

November 12, 2024 16:30 ET | Source: Psyence Biomedical Ltd. NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical…

1 week ago

Pennant Group to Participate in the 2024 Stephens Annual Investment Conference

November 11, 2024 19:14 ET | Source: Pennant Group, Inc. EAGLE, Idaho, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The Pennant…

1 week ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort…

2 weeks ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

2 weeks ago

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FASTs 17th Annual Global Science Summit

November 09, 2024 10:30 ET | Source: Ultragenyx Pharmaceutical Inc. Phase 1/2 data show improvements across all domains and confirm…

2 weeks ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

 Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T…

2 weeks ago